Canagliflozin not only reduces serum urate levels in people with diabetes but also reduces their risk of adverse events attributed to gout. The findings, from research presented at the American Diabetes Association 79th Scientific Sessions in San Francisco recently, suggest the sodium glucose co-transporter 2 (SGLT2) inhibitor may have a future role in managing gout ...
Diabetes drug shows promise for gout
By Mardi Chapman
18 Jun 2019